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Abstract
In anatomical and functional studies of the human and animal urethra, 
the middle urethral contained rhabdosphincter is critical for maintaining 
continence. Transplanted muscle and/or stem cells may have the ability 
to undergo self-renewal and multipotent differentiation, leading to sphinc-
ter regeneration. In addition, such cells may release, or be engineered to 
release, neurotrophins with subsequent paracrine recruitment of endog-
enous host cells to concomitantly promote a regenerative response of 
nerve-integrated muscle. Cell-based therapies include the use of autologous 
multipotent stem cells, such as the bone marrow stromal cells. However, 
harvesting bone marrow stromal stem cells is difficult, painful, and may 
yield low numbers of stem cells upon processing. In contrast, alterna-
tive autologous adult stem cells such as muscle-derived stem cells and 
adipose-derived stem cells can be easily obtained in large quantities and 
with minimal discomfort. We will review the neurophysiology of stress 
urinary incontinence (highlighting the importance of the middle urethra); 
current injectable cell sources for cystoscopic treatment; and the potential 
of muscle-derived cells. [Tzu Chi Med J 2008;20(3):169–176]
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1. Introduction
There are over 200 million people worldwide with 
incontinence, a condition that is associated with social 
impact and a reduced quality of life [1,2]. Stress uri-
nary incontinence (SUI) has been reported as the 
most common type of urinary incontinence [3]. Risk 
factors for developing SUI include increasing parity, 
age, and obesity [4]. Injury during childbirth to pelvic 
floor musculature, connective tissue, and nervous 
structures appears to be the most important risk fac-
tor for urinary incontinence in later life [5–8].
SUI can be grouped into two major categories: ure-
thral hypermobility and intrinsic sphincter deficiency 
(ISD) [9]. Urethral hypermobility, or loss of bladder neck 
support, results in a lack of intra-abdominal pressure 
transmission to the proximal urethra. In contrast, ISD 
is characterized by malfunction of the urethral clo-
sure mechanism. However, the grouping of patients 
into dichotomous categories has not translated into 
diagnostic and therapeutic improvements [10]. Most 
researchers now believe that SUI varies between the 
extremes of urethral hypermobility and ISD, with most 
patients having elements of both disorders [11].
The role of pharmacotherapy for SUI, including α-
adrenoceptor agonists, has been disappointing [12]. 
Duloxetine, a selective serotonin and norepinephrine 
reuptake inhibitor, is available in Europe but it was 
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not approved by the FDA in the United States for the 
indication of SUI [13]. The use of injectable bulking 
agents including polytetrafluoroethylene [14], bovine 
collagen [15], silicone particles [16], carbon beads 
[17], and autologous ear chondrocytes [18] has yielded 
short-term success in the treatment of SUI. However, 
use of bulking agents has resulted in chronic inflam-
matory reactions, foreign body giant cell responses, 
periurethral abscess, particle migration, erosion of the 
urinary bladder or the urethra, obstruction of the lower 
urinary tract with urinary retention, severe voiding 
dysfunction, and pulmonary embolism [19–22].
The potential of stem cell therapy for the regenera-
tive repair of the deficient rhabdosphincter is currently 
at the forefront of incontinence research [23]. Overall, 
the aim of stem cell therapy is to replace, repair, or en-
hance the biological function of damaged tissue or 
organs. There are two general types of stem cells po-
tentially useful for therapeutic treatment, embryonic 
stem cells (ESCs) and adult stem cells. Although the-
oretically appealing, the practical use of ESCs is limited 
due to problems of cell regulation and ethical consid-
erations [24]. In contrast, adult stem cells have no 
significant ethical issues related to their use.
We envision that in the near future, treatment of SUI 
will involve a routine urologist or urogynecologist’s 
office visit in which a muscle biopsy using a small 
caliber needle biopsy device is performed. The biopsy 
is preserved and shipped to a central approved stem 
cell facility for processing, where a number of muscle-
derived cells (MDCs) are isolated, prepared, and stored. 
Within a period of weeks, the MDCs are shipped back 
to the doctor’s office and, using a cystoscopy or spinal 
needle, the cells are injected into the patient’s urethral 
sphincter under local anesthesia (Fig. 1).
2. New concepts in SUI physiology
All of the urethral muscles, pelvic floor muscles, and 
surrounding connective tissues contribute to urethral 
resting tone. When intra-abdominal pressures are in-
creased by coughing, sneezing, or exercise, the ure-
thra is passively or actively closed to prevent urinary 
leakage. This passive urethral closure mechanism 
is well understood. Contraction of the pelvic floor 
muscles (levator ani muscles) pulls the vagina for-
ward toward the pubic symphysis, creating a backstop 
for the urinary tract. This stable backstop compresses 
the two walls of the urethra, preventing urinary leak-
age during elevation of intra-abdominal pressures [25]. 
In addition, the position of the bladder neck is im-
portant for pressure transmission to the properly po-
sitioned structures during increased intra-abdominal 
pressure to remain equal. Descent of the structures 
causes a pressure gradient that can result in urinary 
leakage.
The active urethral closure mechanism that main-
tains urinary continence during elevation of intra-
abdominal pressures is currently still under investigation. 
The external urethral sphincter (EUS), commonly re-
ferred to as the rhabdosphincter, is composed of both 
type I and type II striated muscle fibers located in 
the middle urethra [26]. In addition, urethral smooth 
muscles are deposited in longitudinal and circular 
layers. The urethral muscles are controlled by three 
sets of peripheral nerves: sacral parasympathetic 
nerves (pelvic nerves), thoracolumbar sympathetic 
nerves (hypogastric nerves), and sacral somatic nerves 
(pudendal nerves) (Fig. 2).
Sympathetic preganglionic pathways emerge from 
the thoracolumbar spinal cord, pass through the sym-
pathetic chain ganglia (SCG), the inferior splanchnic 
nerves (ISN), and to the inferior mesenteric ganglia 
(IMG). Preganglionic and postganglionic sympathetic 
axons then travel through the hypogastric nerves to 
the pelvic plexus and the urogenital organs. Parasym-
pathetic preganglionic axons that originate in the 
sacral spinal cord pass through the pelvic nerves to 
ganglion cells located in the pelvic plexus and then 
to distal ganglia in the target urogenital organs. Sacral 
somatic pathways are contained in the pudendal 
nerves, which provide innervation to the EUS. The 
pudendal and pelvic nerves also receive postgangli-
onic axons from the caudal SCG. These three sets of 
nerves contain afferent axons from the lumbosacral 
dorsal root ganglia (DRG) [27].
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Fig. 1 — Diagram showing autologous stem cell injection 
therapy for stress urinary incontinence. Autologous stem 
cells are obtained with a biopsy of tissue, the cells are 
dissociated and expanded in culture, and the expanded 
cells are implanted into the same host. MDSCs = muscle-
derived stem cells.
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Recent studies have reported that the EUS can be 
activated voluntarily or by reflex mechanism elicited 
by bladder distension [28]. Nerve tracts from the cen-
tral nervous system terminate at Onuf’s nucleus in 
the sacral spinal cord and synapse with the pudendal 
nerves. Serotonin and norepinephrine are two key neu-
rotransmitters that stimulate the proximal end of the 
pudendal nerves to control EUS contraction [28–30].
Nerve-mediated active urethral closure mechanism 
that maintains urinary continence during elevation of 
abdominal pressures may be divided into two groups: 
central nervous control passing through Onuf’s nu-
cleus during sneezing or coughing [31,32], and the 
bladder-to-urethral spinal reflex during laughing, 
exercise, or lifting heavy objects [33,34].
In an elegant series of experiments, Kamo et al 
[31–34] demonstrated that an increase in middle ure-
thral pressure during sneezing was caused not only by 
passive transmission of increased abdominal pres-
sure but also by active reflex contractions of the EUS 
and pelvic floor muscles. In addition, they were able 
to show that this sneeze-induced continence reflex 
in the middle urethra is impaired in a rat SUI model 
induced by vaginal distension. In contrast, the in-
crease in proximal and distal urethral pressure during 
sneezing was dependent upon increases in intrave-
sicular and/or intra-abdominal pressure. Another key 
observation was that passive elevation of intravesic-
ular pressure in spinal cord transected rats elicited 
both pelvic afferent nerve-mediated contractile re-
flexes and bladder-to-urethral spinal reflexes in the 
middle-to-proximal urethra mediated by the activation 
of pelvic nerves.
In anatomical reports, Strasser et al [35] showed 
that hypogastric and pelvic nerves predominantly 
innervated and regulated the proximal urethra, whereas 
stimulation of pudendal nerves led to contraction of 
the middle-to-distal urethra. In addition, a decrease 
in the number of striated muscle cells was reported in 
conjunction with an age-dependent increase of ap-
optosis of the striated muscle fibers of EUS [36]. These 
results suggest that the middle urethra and EUS are 
critical for maintaining continence and represent a 
primary focus in the management of SUI.
3. Stress incontinence cellular therapy
Cell-based therapies and tissue engineering are most 
often associated with the use of autologous multipo-
tent stem cells. One commonly described source of 
such cells is the bone marrow stroma. The bone mar-
row compartment contains several cell populations 
including mesenchymal stem cells (MSCs) that are ca-
pable of differentiating into adipogenic [37], osteogenic 
[37], chondrogenic [38], and myogenic cells [39,40]. 
However, autologous bone marrow procurement has 
significant inherent limitations including painful pro-
curement procedures that frequently require general 
or spinal anesthesia, and often yield a low number of 
MSCs upon processing [37]. As an alternative source 
of autologous adult stem cells, MDCs and adipose-
derived stem cells (ADSCs) are advantageous because 
they can be easily obtained in large quantities under 
local anesthesia.
MDC therapy, often referred to as myoblast trans-
fer therapy, has in the past been hindered by numer-
ous limitations including poor survival of the injected 
cells. Selection of specific stem cells from the pool 
of remaining MDC populations, through the use of 
techniques such as pre-plating, has led to improved 
cell survival rates following transplantation [41]. 
Such observations have since led to extensive inves-
tigation into the developmental origins of skeletal 
muscle progenitor cells and the functional heteroge-
neity displayed by various skeletal MDC populations 
[42,43]. While difficult to identify in vitro through 
expression of specific “marker” proteins, which are 
often in flux or may be downregulated quickly follow-
ing placement in culture, MDCs display a remarkable 
regenerative capacity when compared to the com-
monly recognized and abundant striated muscle 
precursor “myoblast” cells. The total regenerative re-
sponse elicited through the transplantation of such 
cells, including their survival, engraftment, induction 
of host tissue repair, and ability to restore functional-
ity is elegantly displayed in a recent report compar-
ing the fate of MDCs and myoblasts in a myocardial 
infarct model [44]. Therefore, not all MDCs are cre-
ated equal and care should be taken when consider-
ing and comparing reports originating from different 
laboratories.
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Fig. 2 — Diagram showing the sympathetic, parasympa-
thetic, and somatic innervation of the urogenital tract. 
IMG= inferior mesenteric ganglia; SCG = sympathetic chain 
ganglia; DRG = dorsal root ganglia; ISN = inferior splanch-
nic nerves; EUS = external urethral sphincter.
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In our ongoing research, MDCs display an improved 
transplantation capacity with the ability to undergo 
long-term proliferation, self-renewal, and multipotent 
differentiation, including differentiation toward en-
dothelial and neuronal lineages [45,46]. MDC injection 
therapy offers several advantages over conventional 
treatments for SUI. The use of cells that are derived 
from the incontinent patient (autologous cell trans-
plantation) will not cause an immunogenic or allergic 
reaction and therefore may persist longer than in-
jected foreign substances such as collagen [47,48]. 
MDCs are uniquely different from fibroblasts and 
smooth muscle cells since MDCs will fuse to form 
post-mitotic multinucleated myotubes. This limits per-
sistent expansion and risk of obstruction that may 
occur with other cell sources such as fibroblasts [49]. 
Finally, MDCs form myotubes and myofibers that 
become innervated into the host muscle. Therefore, 
not only can they serve as a bulking agent, but they 
are also physiologically capable of improving urethral 
sphincter function [50–52].
The feasibility of this concept was first demonstrated 
in rat models of SUI [23,53]. Chermansky et al [54] 
showed that MDCs had integrated within the striated 
muscle layer of the cauterized middle urethra 4 weeks 
after injection. In addition, the striated muscle layer 
of the MDC-injected urethra was contiguous with an 
increase in nervous tissue when compared to those of 
the cauterized urethra injected with only saline solu-
tion. These results suggest that MDCs may have the 
capacity for multipotent differentiation in the host 
urethral tissue or have the capacity to elicit a para-
crine effect resulting in a more complete regenera-
tive muscle-nerve healing response. In addition, the 
increase in leak point pressure (LPP) seen in the groups 
injected with MDCs was significant when compared 
with the saline-injected cauterized rats. Importantly, 
the difference in LPP both 4 and 6 weeks after MDSC 
injection was not significant when compared with the 
uncauterized control rats.
In a recent report, Kwon et al [49] compared MDCs 
and fibroblasts with regard to their potential for res-
toration of urethral function following injection. Using 
LPP for functional comparison, the short-term exper-
iment revealed no significant difference between MDCs 
and fibroblasts, or a combination of both, when the 
cell dosage was equal across the groups. However, 
when the dosage was varied by two 10-fold increases, 
only a high dose of fibroblast injection led to urinary 
retention. Importantly, even high doses of MDCs did 
not result in such adverse events. These results sug-
gest that fibroblasts may be producing a bulking ef-
fect, as evidenced by the increase in LPP, but may also 
make the tissue less compliant. It has been well docu-
mented that the volume and location of synthetic sub-
stance injections are extremely critical to achieve a low 
incidence of adverse events such as retention [55].
Studies supporting the potential of ADSCs are also 
emerging. Zuk et al [56] described the differentiation 
of ADSCs in vitro into adipogenic, myogenic, and os-
teogenic cells in the presence of lineage-specific in-
duction factors. In addition, ADSCs exhibited the 
functional ability to contract and relax in direct re-
sponse to pharmacologic agents [57]. ADSCs may 
also represent an alternative stem cell source for the 
treatment of SUI [58]. Feasibility of ADSC use has 
been suggested through reports of improvements in 
LPP and urethral function in a rat model of SUI when 
animals were injected with ADSCs in conjunction with 
biodegradable microbeads as a carrier [59]. By pro-
viding a potential cost-effective source for genitouri-
nary reconstruction, cell therapies using MDCs and 
ADSCs are emerging as a promising technology for 
the treatment of SUI.
4. Ex vivo delivery of trophic factors
The use of growth factor proteins to promote healing 
is severely hindered by the difficulty of ensuring their 
delivery to the injured site, their short biologic half-
lives, and the rapid clearance of these molecules from 
the bloodstream [60]. Various growth factors appear 
to regulate skeletal myoblast proliferation and dif-
ferentiation, play a role in different stages of muscle 
regeneration, and enhance the healing process [61]. 
It is intriguing that adult knockout mice expressing a 
neutralizing antibody against nerve growth factor (NGF) 
display a severely reduced muscle mass [62]. In ad-
dition to acting as a target derived factor for develop-
ing neurons, NGF has an autocrine effect on myoblast 
proliferation and fusion [63]. In fact, myoblasts express 
low-affinity p75 NGF receptors [64] and high-affinity 
tyrosine kinase A (trkA) NGF receptors [65]. Presence 
of receptor and exposure of myoblasts to NGF resulted 
in upregulation of antiapoptosis/prosurvival proteins.
This suggests that NGF mediates survival of myo-
blasts prior to differentiation and is important for mus-
cle fiber development. Since Schwann cells can survive 
inside the intramuscular nerve trunks of denervated 
skeletal muscles for a 25-month period without ax-
onal contact in rats [66], NGF release by transplanted 
MDCs may also promote axonal regeneration and func-
tional recovery after nerve injury. It stands to reason 
that transplanted MDCs that have the capacity to un-
dergo self-renewal and multipotent differentiation, as 
well as release growth factors such as NGF, may pro-
mote a more complete response due to both auto-
crine and paracrine effects, leading to both a muscle 
and integrated nerve regenerative response of donor 
transplanted and host cells.
In a number of tissues, the development and sur-
vival of sympathetic neurons are dependent on the 
presence of target-derived neurotrophins, of which 
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the best characterized is NGF [67]. Sympathetic acti-
vation of adipocytic β-adrenoceptors induces lypolysis 
and a decrease in the number of adipocytes. This pro-
cess is responsible for a loss of body weight during 
hibernation [68]. A recent study has demonstrated 
that NGF is synthesized and released by white adipose 
tissue with the expression of p75 and trkA NGF re-
ceptors in adipocytes [69]. This suggests that ADSCs 
may also have the potential of releasing NGF and re-
generating urethral malfunction in patients with SUI.
5. Clinical results of cellular therapy
Results of the first clinical studies have recently be-
come available (Table 1). Strasser et al [70] reported 
their comparison of 63 patients undergoing autologous 
myoblast and fibroblast injection versus 28 patients 
undergoing collagen injection for SUI. Under ultrasound 
guidance, a transurethral probe was used to inject 
fibroblasts into the urethral submucosa to treat mu-
cosal atrophy, and myoblasts into the rhabdosphinc-
ter for muscle reconstruction [71]. The myoblasts and 
fibroblasts were obtained from an upper arm biopsy. 
Despite significant increases in Incontinence Quality 
of Life (I-QOL) Instrument Scores and decreases in 
Incontinence Scores in the collagen treated group, 
these results did not translate into clinical improve-
ment, and only two (10%) female patients were cured 
of incontinence. In comparison, 85% of the stem cell-
treated group was cured of incontinence, and thick-
ness of urethra and rhabdosphincter were increased 
significantly at the 12-month follow-up on transure-
thral ultrasonography. Comparing stem cell versus 
collagen injections in female clinical trial participants 
revealed a 91% incontinence cure rate in the stem 
cell-treated group compared to 10% in the collagen-
treated group [72]. Efficacy at 2 years (89% cure, 11% 
improvement) was demonstrated in 20 female patients 
from the same study [73]. However, in these studies, 
fibroblasts were mixed with 2.5 mL of collagen as 
carrier material to prevent site migration. The frac-
tional benefit of myoblasts versus fibroblasts versus 
collagen used in the mixed cellular plus collagen in-
jection approach is unclear. Randomized, controlled 
clinical trials are necessary to clarify the benefit of 
the mixed cellular plus collagen injection therapy.
Pure cellular clinical therapy with MDCs obtained 
from biopsies of the lateral thigh were reported by 
Carr et al [74] at the 2006 AUA annual meeting, and 
represented the first trial of North American patients. 
Eight patients received treatment using either a trans-
urethral or periurethral injection into the middle ure-
thra and EUS. The two transurethral injections using 
a 10-mm needle and the two periurethral injections 
resulted in measurable improvement, but the two ini-
tial injections using the shorter 8-mm needle were not 
effective. Five of the eight patients with follow-up for 
over 1 year reported significant improvement occurring 
between 3 and 8 months after injection (mean follow-up 
of 16.5 months). In addition, cystoscopy at study exit 
and surgical exploration in two patients at the time 
of midurethral tape surgery did not demonstrate any 
appreciable tissue change. Subsequent midurethral 
tape placement and outcome was not negatively im-
pacted upon by previous MDC injection. These results 
suggest the ability of pure cellular therapy to treat SUI 
and emphasize the importance of proper cell place-
ment in resulting effectiveness. Onset of improvement 
was delayed following injection, suggesting that restor-
ing muscle function may be the mechanism of action 
in comparison to standard bulking agents. Deeper 
delivery of MDCs into the external sphincter appears 
to be important for successful outcome.
6. Conclusions
The transvaginal tape (TVT) procedure has gained 
popularity for the treatment of SUI. Several authors 
have reported on the surgical outcome of TVT proce-
dures, demonstrating 85–89% objective cure rates 
at 3 or 5 years [75–77]. In contrast, Ward and Hilton 
[78] published the largest randomized, controlled trial 
comparing subjective and objective outcomes after 
abdominal colposuspension or insertion of TVT. At 
2 years, 63% of the TVT group and 51% of the colpo-
suspension group were objectively cured. The sub-
jective cure rates at 2 years, however, were only 43% 
and 37%, respectively.
Table 1 — Early results of initial clinical studies examining the efficacy of adult stem cell therapy for stress urinary 
incontinence
Clinical study Patients (n) Method of delivery Stem cell source Symptomatic improvement
Strasser et al [70] 63 TUUS Autologous myoblasts and fibroblasts* 85%
Strasser et al [72] 42 TUUS Autologous myoblasts and fibroblasts* 91%
Mitterbarger et al [73] 20 TUUS Autologous myoblasts and fibroblasts* 90% at 1 yr
    89% at 2 yr
Carr et al [74]  8 TUUS, EI, DPI Pure MDSCs 63%
*Mixed cellular plus collagen injections. TUUS = transurethral ultrasound; EI = endoscopic injection; DPI = direct periurethral injection; MDSCs =
muscle-derived stem cells.
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Suburethral sling procedures are regarded as a 
hammock to reinforce the weakness of pelvic floor 
muscles and supportive ligaments or fascia, whereas 
stem cell injection therapy into the middle urethra 
may restore the contractile response of the striated 
muscle and rhabdosphincter. The hope is that stem 
cell treatment of SUI will result in improved cure rates 
with minimal risks. Not all cellular therapies are the 
same, as demonstrated by the differences in safety 
and efficacy among MDCs, myoblasts, and fibroblasts. 
Autologous MDC and ADSC pure injection therapy 
may be a promising treatment to restore urethral 
sphincter function.
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